Calcium channel drugs and uses

1. A compound of the formula:

L-X-L

or a pharmaceutically-acceptable salt thereof;

wherein one L is a ligand of formula (A):

and the other L is a ligand independently selected from the group consisting of formulae (A), (C), (D), (E), (F), (G), and (H):

X is a linker of the formula:

—X′-Z-(Y″-Z) m -Y″-Z-X′—

in which:

m is an integer of from 0 to 20;

X′ at each separate occurrence is —O—, —S—, —S(O)—, —S(O) 2 —, —NR—, —N + RR′, —C(O)—, —C(O)O—, —C(O)NH—, —C(S)—, —C(S)O—, —C(S)NH— or a covalent bond, where R and R′ at each separate occurrence are as defined below for R′ and R″;

Z is at each separate occurrence selected from alkylene, substituted alkylene, alkylalkoxy, cycloalkylene, substituted cycloalkylene, alkenylene, substituted alkenylene, alkynylene, substituted alkynylene, cycloalkenylene, substituted cycloalkenylene, arylene, substituted arylene, heteroarylene, heterocyclene, substituted heterocyclene, crown compounds or a covalent bond;

Y′ and Y″ at each separate occurrence are selected from —S—S—, a covalent bond or a structure selected from the following group:

in which:

n is 0, 1 or 2; and

R′ and R″ at each separate occurrence are selected from hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, heteroaryl or heterocyclic.

2. The compound of claim 1 , wherein both L are ligands of formula (A).

3. The compound of claim 1 , wherein one L is a ligand of formula (A) and the other L is a ligand of formula (C).

4. The compound of claim 1 , wherein one L is a ligand of formula (A) and the other L is a ligand of formula (D).

5. The compound of claim 1 , wherein one L is a ligand of formula (A) and the other L is a ligand of formula (E).

6. The compound of claim 1 , wherein one L is a ligand of formula (A) and the other L is a ligand of formula (F).

7. The compound of claim 1 , wherein one L is a ligand of formula (A) and the other L is a ligand of formula (G).

8. The compound of claim 1 , wherein one L is a ligand of formula (A) and the other L is a ligand of formula (H).

9. The compound according to claim 1 , wherein the compound is selected from compound numbers (8), (82), (133), (168), (170), (190), (498), and (610):

10. A compound according to claim 1 , wherein X is selected from the group consisting of:

 (1)

 (2)

 (3)

 (4)

 (5)

 (6)

 (7)

 (8)

 (9)

(10)

(11)

(12)

(13)

(14)

(15)

(16)

(17)

(18)

(19)

(20)

(21)

(22)

(23)

(24)

(25)

(26)

(27)

(28)

(29)

(30)

(31)

(32)

(33)

(34)

(35)

(36)

(37)

11. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a therapeutically effective amount of a compound of claim 1 .

12. A method for treating a disease or condition in a mammal resulting from an activity of a Ca ++ channel, which method comprises administering to said mammal a therapeutically effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable excipient and one or more compounds of claim 1 .